Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 3 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 38 Neoplasm Metastasis 9 Brain Neoplasms 6 Stomach Neoplasms 3 Colorectal Neoplasms 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasms 2 Neoplasm, Residual 2 Meningeal Carcinomatosis 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Cancer With Brain Metastasis 2 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Inflammatory Breast Neoplasms 1 HER2-positive Breast Cancer 1 HER2-negative Breast Cancer 1 HER2 Overexpression 1 Glioblastoma 1 Gastric Adenocarcinoma 1 Drug-Related Side Effects and Adverse Reactions 1 Colonic Neoplasms 1 Breast Cancer Metastatic 1 Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 156 Paclitaxel 154 Bevacizumab 96 Cyclophosphamide 61 Gemcitabine 46 olaparib 45 Cisplatin 45 Topotecan 44 niraparib 40 liposomal doxorubicin 40 pembrolizumab 38 Surveys and Questionnaires 33 Filgrastim 31 Hyperthermic Intraperitoneal Chemotherapy 29 Docetaxel 27 Taxes 25 Blood Specimen Collection 24 fludarabine 23 Drug Therapy 23 Cytoreduction Surgical Procedures 23 Peripheral Blood Stem Cell Transplantation 21 Etoposide 21 Doxorubicin 21 Magnetic Resonance Spectroscopy 20 durvalumab 17 Specimen Handling 17 Albumin-Bound Paclitaxel 17 Immunoglobulin G 15 Disulfides 15 Letrozole 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Ovarian Neoplasms × trastuzumab deruxtecan × Clear all

NCT07340164 2026-04-20

TROY

Yonsei University

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡